Abdorreza Naser Moghadasi, Saeed Vaheb, Sara Hamtaei-Ghashti, Aysa Shaygannejad, Mozhdeh Askari, Vahid Shaygannejad, Mohmmad Ali Sahraian, Mahsa Ghajarzadeh
{"title":"COVID-19大流行期间多发性硬化症患者对再感染、复发和焦虑的恐惧:一项多中心研究","authors":"Abdorreza Naser Moghadasi, Saeed Vaheb, Sara Hamtaei-Ghashti, Aysa Shaygannejad, Mozhdeh Askari, Vahid Shaygannejad, Mohmmad Ali Sahraian, Mahsa Ghajarzadeh","doi":"10.18502/cjn.v22i2.13332","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Fear of relapse and re-infection during the coronavirus disease 2019 (COVID-19) pandemic can affect people with chronic relapsing diseases, such as multiple sclerosis (MS). We evaluated fear of re-infection, anxiety, and relapse during the COVID-19 pandemic in Iranian people with MS. <b>Methods:</b> This multicenter, cross-sectional study was performed in the MS clinic of Sina Hospital, Tehran, Iran, and Hakim Private Hospital, Isfahan, Iran, between January and April 2022. We asked the participants to fill out validated Persian versions of Fear of Relapse Scale (FoR), and Beck Anxiety Inventory (BAI) questionnaires and answer a binary question about their fear of getting reinfected with COVID-19. Results were reported as mean ± standard deviation (SD) for continuous variables or frequencies for categorical variables. For continuous variables which did not have a normal distribution, we reported the median and interquartile range (IQR). Spearman correlation coefficient between anxiety score and FoR score was calculated. An independent samples t-test was used to compare continuous variables. <b>Results:</b> Three hundred and sixty-eight patients participated in this study. The median scores of FoR and BAI were 49.7 and 34.3, respectively. Fifty-three had new relapses in their last infection. Thirty-six percent of the patients had a fear of getting COVID-19 again, and 43% had a fear of relapse during infection. Three hundred and twenty-three had two doses of COVID-19 vaccine; the most frequent type of vaccine was Sinopharm. There was a significant difference between the median FoR scores among patients with and without relapse during the last COVID-19. There was also a significant positive correlation between anxiety score and FoR (r = 0.49, P < 0.001). <b>Conclusion:</b> More than one-third of enrolled cases had fear of severe acute respiratory syndrome coronavirus 2 <b>(</b>SARS-CoV-2) re-infection. Patients who experienced exacerbation of symptoms even in the form of relapse or pseudo relapse (possible clinical relapse) had a higher fear of infection.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"22 1","pages":"82-86"},"PeriodicalIF":0.5000,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460923/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fear of re-infection, relapse, and anxiety during COVID-19 pandemic in patients with multiple sclerosis: A multi-center study.\",\"authors\":\"Abdorreza Naser Moghadasi, Saeed Vaheb, Sara Hamtaei-Ghashti, Aysa Shaygannejad, Mozhdeh Askari, Vahid Shaygannejad, Mohmmad Ali Sahraian, Mahsa Ghajarzadeh\",\"doi\":\"10.18502/cjn.v22i2.13332\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Fear of relapse and re-infection during the coronavirus disease 2019 (COVID-19) pandemic can affect people with chronic relapsing diseases, such as multiple sclerosis (MS). We evaluated fear of re-infection, anxiety, and relapse during the COVID-19 pandemic in Iranian people with MS. <b>Methods:</b> This multicenter, cross-sectional study was performed in the MS clinic of Sina Hospital, Tehran, Iran, and Hakim Private Hospital, Isfahan, Iran, between January and April 2022. We asked the participants to fill out validated Persian versions of Fear of Relapse Scale (FoR), and Beck Anxiety Inventory (BAI) questionnaires and answer a binary question about their fear of getting reinfected with COVID-19. Results were reported as mean ± standard deviation (SD) for continuous variables or frequencies for categorical variables. For continuous variables which did not have a normal distribution, we reported the median and interquartile range (IQR). Spearman correlation coefficient between anxiety score and FoR score was calculated. An independent samples t-test was used to compare continuous variables. <b>Results:</b> Three hundred and sixty-eight patients participated in this study. The median scores of FoR and BAI were 49.7 and 34.3, respectively. Fifty-three had new relapses in their last infection. Thirty-six percent of the patients had a fear of getting COVID-19 again, and 43% had a fear of relapse during infection. Three hundred and twenty-three had two doses of COVID-19 vaccine; the most frequent type of vaccine was Sinopharm. There was a significant difference between the median FoR scores among patients with and without relapse during the last COVID-19. There was also a significant positive correlation between anxiety score and FoR (r = 0.49, P < 0.001). <b>Conclusion:</b> More than one-third of enrolled cases had fear of severe acute respiratory syndrome coronavirus 2 <b>(</b>SARS-CoV-2) re-infection. Patients who experienced exacerbation of symptoms even in the form of relapse or pseudo relapse (possible clinical relapse) had a higher fear of infection.</p>\",\"PeriodicalId\":40077,\"journal\":{\"name\":\"Current Journal of Neurology\",\"volume\":\"22 1\",\"pages\":\"82-86\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460923/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Journal of Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/cjn.v22i2.13332\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Journal of Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/cjn.v22i2.13332","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:在2019冠状病毒病(COVID-19)大流行期间,对复发和再感染的恐惧可能会影响多发性硬化症(MS)等慢性复发性疾病患者。我们评估了2019冠状病毒病大流行期间伊朗多发性硬化症患者对再感染、焦虑和复发的恐惧。方法:这项多中心横断面研究于2022年1月至4月在伊朗德黑兰Sina医院和伊斯法罕Hakim私立医院的多发性硬化症诊所进行。我们要求参与者填写波斯语版本的恐惧复发量表(FoR)和贝克焦虑量表(BAI)问卷,并回答一个关于他们害怕再次感染COVID-19的二元问题。结果以连续变量的平均值±标准差(SD)或分类变量的频率报告。对于不具有正态分布的连续变量,我们报告了中位数和四分位数范围(IQR)。计算焦虑评分与FoR评分之间的Spearman相关系数。采用独立样本t检验比较连续变量。结果:368例患者参与了本研究。FoR和BAI的中位数分别为49.7分和34.3分。53例在最后一次感染中有新的复发。36%的患者担心再次感染COVID-19, 43%的患者担心感染期间复发。323人接种了两剂COVID-19疫苗;最常见的疫苗类型是国药控股。在最后一次COVID-19期间复发和未复发患者的中位数评分之间存在显着差异。焦虑评分与FoR也有显著正相关(r = 0.49, P < 0.001)。结论:超过三分之一的病例对SARS-CoV-2再次感染有恐惧。经历症状加重甚至复发或假性复发(可能的临床复发)的患者对感染有更高的恐惧。
Fear of re-infection, relapse, and anxiety during COVID-19 pandemic in patients with multiple sclerosis: A multi-center study.
Background: Fear of relapse and re-infection during the coronavirus disease 2019 (COVID-19) pandemic can affect people with chronic relapsing diseases, such as multiple sclerosis (MS). We evaluated fear of re-infection, anxiety, and relapse during the COVID-19 pandemic in Iranian people with MS. Methods: This multicenter, cross-sectional study was performed in the MS clinic of Sina Hospital, Tehran, Iran, and Hakim Private Hospital, Isfahan, Iran, between January and April 2022. We asked the participants to fill out validated Persian versions of Fear of Relapse Scale (FoR), and Beck Anxiety Inventory (BAI) questionnaires and answer a binary question about their fear of getting reinfected with COVID-19. Results were reported as mean ± standard deviation (SD) for continuous variables or frequencies for categorical variables. For continuous variables which did not have a normal distribution, we reported the median and interquartile range (IQR). Spearman correlation coefficient between anxiety score and FoR score was calculated. An independent samples t-test was used to compare continuous variables. Results: Three hundred and sixty-eight patients participated in this study. The median scores of FoR and BAI were 49.7 and 34.3, respectively. Fifty-three had new relapses in their last infection. Thirty-six percent of the patients had a fear of getting COVID-19 again, and 43% had a fear of relapse during infection. Three hundred and twenty-three had two doses of COVID-19 vaccine; the most frequent type of vaccine was Sinopharm. There was a significant difference between the median FoR scores among patients with and without relapse during the last COVID-19. There was also a significant positive correlation between anxiety score and FoR (r = 0.49, P < 0.001). Conclusion: More than one-third of enrolled cases had fear of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) re-infection. Patients who experienced exacerbation of symptoms even in the form of relapse or pseudo relapse (possible clinical relapse) had a higher fear of infection.